GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Wednesday August 26, 2009

PennyOmega.com Stock Report!

**************************************************************

Raser Technologies, Inc. (NYSE: RZ), an energy technology company, announced results from a recent test drive demonstrating over 50 miles of all-electric range by its electric Hummer H3E during a preliminary road test.

TIBCO Software Inc. (NASDAQ: TIBX), today announced the general availability of TIBCO Collaborative Information Manager(TM) version 7.2.1 — the first enterprise master data management (MDM) platform to provide out-of-the box functionality that offers customers powerful new tools to address their data integrity challenges using machine intelligence.

Guardian Technologies International, Inc. (OTCBB: GDTI) today announced that its Software Quality Assurance Team has completed all unit, component, integration,

...

Bio-Solutions Corp. focuses on veterinary care and organic dietary supplements for livestock and domestic animals. The company announced last week it will market an organic insecticide to combat Malaria.

GreenExTM is available in solid or liquid form, and works by neutralizing and eradicating up to 98 percent of mosquito larvae within a 24-hour period. Malaria is a life threatening disease, infecting more than 250 million people each year and killing more than 1 million children under the age of five each year. The disease isn’t geographically restricted, but thrives in tropical and subtropical regions. According to the company, GreenExTM can be used for humans, as well as animals.

“This organic product can be as useful in veterinary care as for human care; Bio-Solutions will advocate a specialized market strategy for GreenExTM. We will offer this product as a viable alternative to the countries dissatisfied of the service offered by the

...

Bill Gates, founder of Microsoft (MSFT) a href=”http://news.yahoo.com/s/afp/20090205/ts_alt_afp/usitinternethealthfinancegates” target=”_blank”released a jar of mosquitoes/a at a conference to spread the word about malaria.div class=”blogger-post-footer”div class=’adsense’ style=’text-align:center; padding: 0px 3px 0.5em 3px;’
script type=”text/javascript”!–
google_ad_client=”ca-pub-2427831169011625″;
google_ad_width=300;
google_ad_height=250;
google_ad_format=”300×250_as”;
google_ad_type=”text”;
google_ad_channel =”8681602088″;
google_color_border=”FFF3DB”;
google_color_bg=”FFF3DB”;
google_color_link=”1B0431″;
google_color_url=”1B0431″;
google_color_text=”29303B”;
//–/script
script type=”text/javascript”
src=”http://pagead2.googlesyndication.com/pagead/show_ads.js”
/script
/div

El Dorado … Cibola … Quivira … these are all fabled “lost cities of gold” that fired up the imaginations of explorers who pursued their dreams to the four corners of the Earth. These cities only existed in the fevered imaginations of storytellers. But there was a real city of gold … or at least, a city richly associated with gold. Its discovery by European explorers is the story of unlocking mysterious Africa … a tale that rings down through the ages … and holds lessons for investors today. Timbuktu’s distance and fabled wealth fired the imaginations of early explorers. The ...

GenVec, Inc. reported today that the U.S. Food and Drug Administration (FDA) has approved GenVec’s TNFerade™ for Fast Track development in the treatment of locally advanced pancreatic cancer. TNFerade™ is designed to stimulate the production of immune system proteins with anti-cancer properties that are injected into tumors. GenVec is developing TNFerade™ for use in combination with other tools such as radiation and chemotherapy for the treatment of various cancers.

TNFerade™ qualifies for Fast Track status because GenVec provided the FDA with evidence that TNFerade™ may have potential to improve the survival rate of patients suffering from pancreatic cancer. The FDA grants Fast Track designation to drugs that are designed to treat life-threatening conditions and that have a proven potential to address an unmet medical need.

Fast Track designation only applies to situations where a developmental stage drug is used to treat one specific

...

GenVec, Inc. (NASDAQ: GNVC) announced Thursday that it received a third year option of funding, as part of a five-year contract with the National Institute of Allergy and Infectious Disease. The company will receive up to $3.8 million to continue the development of new HIV vaccine candidates. GenVec’s research is based on its proprietary adenovirus vector and production cell line technologies.

“We appreciate NIAID’s decision to execute its renewal option under our contract,” said Dr. Rick King, GenVec’s senior vice president of research and development. “GenVec’s adenovector technology platform now includes six distinct serotypes that can be used singly or in combination.”

GenVec and the NIAID Vaccine Research Center have partnered on HIV vaccine development under a Collaborative Research and Development Agreement for several years. Under a separate contract, GenVec has produced adenovector-based HIV vaccines that have been tested in about 1,400 subjects in 16 NIAID-sponsored Phase I and Phase II clinical

...

Immtech Pharmaceuticals (IMM) is an early stage biotechnology working on cures and treatments for infectious diseases such as African Sleeping Sickness and Pneumocystis pneumonia (PCP). While these diseases are rare in the developed world, they infect millions, if not billions, of people in the third world, meaning the market for Immtechs products could be nearly limitless at some point. The company is also working on a cure for malaria and sports a strong library of compounds aimed at treating bacterial and fungal infections, along with Hepatitis C.

Last month, Immtech reported a surge in fiscal first quarter sales along with a significantly narrower per share loss. For the three months ended June 30, 2008, revenues were $1,141,000, as compared to $826,000 for the three months ended June 30, 2007. The increase was primarily attributable to revenues from a research and testing agreement. Immtech’s net loss for the period was $1,383,000, or

...

Sinobiomed (SOBM) is a Chinese developer of genetically engineered recombinant protein drugs and vaccines. The company’s drugs treat diseases and ailments such as malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Sinobiomed currently has 10 products: three on the market, four in clinical trials and three in research and development.

Sinobiomed, based in the bustling metropolis of Shanghai, could be on the forefront of the burgeoning Chinese biotechnology industry. China’s biotech industry is expected to continue its rapid expansion of 20 percent to 30 percent annually to $8.5 billion by 2010 helped by government contributions of $600 million annually. The Chinese pharmaceutical industry is expected to be the world’s 5th largest market by 2010.

Sinobiomed is considered a market leader in the area of recombinant protein drugs and recently acquired a distributor to facilitate a more expeditious sale of some its drugs. The

...

Sinobiomed Inc. (SOBM.OB) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Sinobiomed employs a patented low-cost, high yield production process to enhance bioactivity and guarantee the highest levels of purity.

Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials, and three in R&D. The company’s products respond to a wide range of diseases and conditions, including: hepatitus B&C, surgical bleeding, diabetic ulcers and burns, malaria, cancer, rheumatoid arthritis, acute liver disease, stroke, blood clots and thrombosis, acute pancreatitis, and blood cell regeneration.

Sinobiomed has several competitive advantages in addition to the company’s patented recombinant protein manufacturing process. One advantage is the company’s strong strategic alliances with leading Chinese research hospitals and institutes for collaborative development of patentable techniques and treatments. Another advantage is the company’s distribution network.

Sinobiomed has also established a nationwide sales and marketing network along with international

...